Vanda Pharmaceuticals | VNDA - Los Gastos De Explotación





Los Gastos De Explotación Cambio Fecha
Acadia Pharmaceuticals USD 270.12M 2.55M 2026-06
Agios Pharmaceuticals USD 130.77M 10.77M 2026-03
Akebia Therapeutics USD 63.08M 8.26M 2025-12
Alnylam Pharmaceuticals USD 1.06B 160.97M 2026-06
Anika Therapeutics USD 137.28M 3.38M 2026-06
Arrowhead Research USD 245.35M 30.35M 2026-06
AstraZeneca USD 12.22B 4.04B 2026-06
Bristol-Myers Squibb USD 22.32B 2.25B 2026-06
Eli Lilly USD 10.52B 496M 2026-06
Enanta Pharmaceuticals USD 126.59M 346.51M 2025-12
Halozyme Therapeutics USD 193.34M 1.15M 2026-06
Heron Therapeutics USD 40.55M 1.46M 2025-12
Insmed USD 526.79M 20.55M 2026-06
J&J USD 17.83B 388M 2026-06
Lexicon Pharmaceuticals USD 20.27M 6.1M 2025-12
Ligand Pharmaceuticals USD 55.1M 20.75M 2026-06
Merck USD 15.77B 2.4B 2026-06
Minerva Neurosciences USD 4.52M 155.46K 2024-12
Moderna USD 960M 817M 2026-06
Novartis USD 9.29B 507M 2026-03
Pfizer USD 85.19B 4.91B 2026-06
PTC Therapeutics USD 226.66M 19.64M 2026-03
Puma Biotechnology USD 49.26M 3.2M 2024-06
Sangamo BioSciences USD 33.87M 12.89M 2024-06
Sanofi EUR 9.92B 607M 2026-06
Takeda JPY 1.02T 89.68B 2026-06
Teva Pharmaceutical Industries USD 3.92B 691M 2026-06
Ultragenyx Pharmaceutical USD 289M 16M 2026-06
Vanda Pharmaceuticals USD -1.14B 1.6B 2025-12
Veracyte USD 126.36M 6.37M 2026-06